GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] the GIP rule is doing its job and people should stop complaining — 44 comments in the full submission. View in context.
11k
c/tirzepatide·submitted 1 year ago by u/kaia_wojcik

[Meta] the GIP rule is doing its job and people should stop complaining

Trial Databranch of 7 comments

Putting this to the board: the GIP rule is doing its job and people should stop complaining. On comparing yourself with the trial number. SURMOUNT-1 reported roughly 21% mean body weight change at 72 weeks on the highest arm. Three things get dropped every time that figure is quoted here. It is a mean, and the…

Read the full submission and all 44 comments →

This branch

7 comments, started 1 year ago
u/sten_palacios2.2k points·1 year ago

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

replysharereportpermalink
u/amara_halonen1.4k points·1 year ago

Same experience with the appetite effect being flatter across the week rather than front-loaded.

replysharereportpermalink
u/incretin_ivypharmacology1.8k points·1 year ago

the four-week step schedule is the label, not folklore

replysharereportpermalink
u/spain_receta1.4k points·1 year ago

pens and vials are the same molecule, the price is the difference

replysharereportpermalink
u/cato_girard474 points·1 year ago

This matches mine. Milder injection-site soreness than I expected, and what there was settled inside a fortnight of each step.

replysharereportpermalink
u/line_petrov518 points·1 year ago

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

replysharereportpermalink
u/hub_opssite staff223 points·1 year ago

if 7.5 is working, 10 is not automatically better

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.